CD274 and hepatocellular carcinoma: In 2020, we witnessed a new milestone in the systemic treatment landscape of HCC when a 5.8-month survival advantage over sorafenib was demonstrated with the combination of atezolizumab (anti-PDL1) and bevacizumab (anti-vascular endothelial growth factor [VEGF]) in the IMBRAVE-150 study [14].